Lantern Pharma Inc (LTRN)

Etorro trading 970x250
Lantern Pharma Inc (LTRN) Logo

About Lantern Pharma Inc

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201

Lantern Pharma Inc News and around…

Latest news about Lantern Pharma Inc (LTRN) common stock and company :

12 Health Care Stocks Moving In Friday's Intraday Session
08 Oct, 2021 FinancialContent

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 ...

12 Health Care Stocks Moving In Thursday's Intraday Session
07 Oct, 2021 FinancialContent

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of ...

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
07 Oct, 2021 FinancialContent

Upgrades For State Street Corporation (NYSE:STT), Wolfe Research upgraded the previous rating of Peer Perform to ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
04 Oct, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th \- 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Fall Harvest - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, October 5th, 2021, with company presentations beginning at 8:30 am Eastern Time.

Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
30 Sep, 2021 FinancialContent
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer
28 Sep, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development and Deep Lens, a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of diagnosis, today announced that they have entered into a strategic collaboration that will leverage Deep Lens' artific

Lantern Pharma CEO to Present at the Benzinga Healthcare Small Cap Conference on September 29th
22 Sep, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, President & CEO of Lantern Pharma will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 – 30, 2021.

Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September
07 Sep, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will be participating in two upcoming virtual investor conferences.

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives
02 Sep, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where hi

Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication
30 Aug, 2021 FinancialContent

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for glioblastoma multiforme (GBM) and ...

FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas
30 Aug, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation (ODD) for the treatment of glioblastoma multiforme (GBM) and other malignant gliomas. This news follows the recent announcement of the FDA granting LP-184 ODD for

54 Biggest Movers From Yesterday
26 Aug, 2021 FinancialContent

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
25 Aug, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 100.19% to $30.63 during Wednesday's regular session. Regencell ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock
19 Aug, 2021 FinancialContent

Lantern Pharma Inc(NASDAQ: LTRN)announced preclinical dataof its drug candidate LP-184, showing its potential to ...

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
19 Aug, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma (GBM). This study was conducted in collaboration with the research group of John Laterra, M.D., Ph.D., at Kennedy Krieger Institute, which is affiliated with Johns Hopkins University. Lantern had previously announced the initiation of this GBM focused

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
16 Aug, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects' has been accepted as a virtual poster at the upcoming AACR Virtual Special Conference on Pancreatic Cancer

Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
11 Aug, 2021 FinancialContent

TheFDA has granted Orphan Drug DesignationtoLantern Pharma Inc's(NASDAQ: LTRN) LP-184 for pancreatic ...

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
11 Aug, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation for the treatment of pancreatic cancer. LP-184 is a small molecule drug candidate and next generation alkylating agent that preferentially damages DNA in cancer c

How Many Lantern Pharma Inc. (NASDAQ:LTRN) Shares Do Institutions Own?
09 Aug, 2021 Yahoo! Finance

Every investor in Lantern Pharma Inc. ( NASDAQ:LTRN ) should be aware of the most powerful shareholder groups...

LTRN: 2Q:21 Results
05 Aug, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Second Quarter 2021 Financial and Operational Results On July 29, 2021, Lantern Pharma, Inc. (NASDAQ:LTRN) announced second quarter 2021 financial and operational results, filed its form 10-Q with the SEC and hosted a conference call to review the quarter’s accomplishments. Highlights for year-to-date 2021 include: ➢

Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights
29 Jul, 2021 Yahoo! Finance

Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern"), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced financial results for the second quarter ended June 30, 2021.

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
27 Jul, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity, formerly known as Oncology Venture. This transaction includes global rights to the clinical stage drug cand

A Peek Into The Markets: US Stock Futures Down Following Friday's Rally
26 Jul, 2021 FinancialContent

Pre-open movers U.S. stock futures traded lower in early pre-market trade after all three major indexes settled at record highs in ...

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
25 Jul, 2021 FinancialContent

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism ...

Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
22 Jul, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss financial and operating results for the second quarter ended J

Lantern Pharma Inc (LTRN) is a NASDAQ Common Stock listed in , ,

970x250